The UK and US have concluded a significant bilateral deal that will keep no duties on UK pharmaceutical shipments going into the American market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has agreed to increase spending on pharmaceuticals through the public health system. This move ensures that tariffs on these vital exports will remain at zero for a period of three years.
This deal is in response to earlier threats to dramatically increase duties on branded drug imports, with increases mentioned as high as one hundred percent.
"This agreement with the UK reinforces the international landscape for innovative medicines and introduces much-needed equity to U.S.–U.K. pharmaceutical trade," a statement said.
Commercial Impact
Pharmaceuticals are one of the Britain's biggest exports to the US, which is clearly the biggest market for major UK drugmakers.
Statistics indicate that in the year to the end of the third quarter, the UK exported pharmaceutical products totaling billions to the US. This value represented 17.4% of total UK exports in that period.
"This deal protects work, boosts funding and sets the stage for the UK to establish itself as a international leader for medical research," a government official commented.
Key NHS Changes
The pact includes several specific changes from the UK:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it considers new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a goal to double overall health service expenditure on drugs from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount pharmaceutical firms must return to the NHS to control costs will be limited at 15%. In the past, rebates were more than 20%.
Recent Tensions
The deal takes place against a ongoing row between the sector and the ministers over drug pricing and NHS adoption.
This friction were heightened by claims that American consumers were charged a premium for the equivalent treatments than consumers in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or abandoned, while substantial expansions have been directed toward American operations.
A senior figure stated that the NHS must increase expenditure on drugs, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the past decade.
